Walgreens Moisturizing Ultra Fine Mist with Aloe

Description

Oxymetazoline hydrochloride is a nasal decongestant formulated at a concentration of 0.05%. This product is presented in a dosage form of a nasal solution, with a net weight of 0.5 fluid ounces (15 milliliters).

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, and upper respiratory allergies. It also provides temporary relief of sinus congestion and pressure. The formulation works by shrinking swollen membranes, facilitating easier breathing.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Before the initial use, the protective cap must be removed from the tip, and the pump should be primed by firmly depressing it several times.

For administration, the bottle should be held with the thumb at the base and the nozzle positioned between the first and second fingers. The nozzle should be inserted into the nostril without tilting the head. The rim should be fully depressed with a firm and even stroke while the patient sniffs deeply.

After each use, the nozzle should be wiped clean to maintain hygiene.

For adults and children aged 6 to under 12 years (with adult supervision), the recommended dosage is 2 to 3 sprays in each nostril, not to exceed every 10 to 12 hours. It is important not to exceed 2 doses within a 24-hour period.

For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Contraindications

Use is contraindicated in patients who exceed the directed dosage or utilize the product for more than three consecutive days. Prolonged or frequent use may lead to a recurrence or worsening of nasal congestion.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product to ensure safe and effective administration.

General precautions must be observed to minimize risks. It is imperative that the product is not used in excess of the recommended dosage. Users should refrain from utilizing the product for more than three consecutive days, as prolonged or frequent use may lead to a recurrence or worsening of nasal congestion. Patients may experience temporary discomfort, which can manifest as burning, stinging, sneezing, or an increase in nasal discharge. Additionally, it is crucial to note that sharing this container among multiple users may facilitate the spread of infection.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if symptoms persist, ensuring that appropriate follow-up care is provided.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. It is important to consult a healthcare professional before use, particularly for individuals with pre-existing conditions such as heart disease, high blood pressure, diabetes, thyroid disease, or those experiencing trouble urinating due to an enlarged prostate gland.

In clinical trials, various adverse reactions were reported, although specific data regarding the frequency and seriousness of these reactions were not provided. Additionally, postmarketing experiences may reveal further insights into the safety profile of the medication, but such data is not detailed here.

Patients are advised to discuss any concerns with their healthcare provider to ensure safe and effective use of the medication, particularly if they fall into the aforementioned categories.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Walgreens Moisturizing Ultra Fine Mist with Aloe (0.05% oxymetazoline). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may receive 2 or 3 sprays in each nostril, administered no more frequently than every 10 to 12 hours. It is important to note that the total dosage should not exceed 2 doses within a 24-hour period. For children under 6 years of age, consultation with a healthcare professional is advised prior to use.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully known. Therefore, it is essential for women of childbearing potential to seek medical advice to weigh the benefits and risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, healthcare providers should evaluate the potential risks and benefits when considering the use of this medication in lactating individuals.

Renal Impairment

Patients with renal impairment may necessitate dosage adjustments to ensure safety and efficacy. It is essential for healthcare professionals to monitor creatinine clearance in patients with reduced renal function. Regular renal function tests should be performed to assess kidney health and guide treatment decisions. Additionally, special monitoring is required for patients with significant renal impairment to mitigate potential risks associated with medication use.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. It is advisable to consult local poison control centers or relevant medical authorities for guidance on management protocols specific to the medication in question.

Documentation of the incident, including the amount ingested and the time of exposure, is crucial for effective management and follow-up care. Continuous assessment of the patient's condition is necessary to address any complications that may arise from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the understanding of potential risks associated with the compound in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients to discontinue use and consult a doctor if symptoms persist beyond the initial treatment period.

Patients should be cautioned against exceeding the recommended dosage and should not use the product for more than three consecutive days. Emphasize that frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Inform patients that temporary discomfort, including burning, stinging, sneezing, or an increase in nasal discharge, may occur during use. Additionally, healthcare providers should highlight the risk of infection transmission if the container is used by more than one person.

Before initiating treatment, patients should be encouraged to consult with their healthcare provider if they have a history of heart disease, high blood pressure, diabetes, thyroid disease, or difficulty urinating due to an enlarged prostate gland.

Storage and Handling

The product is supplied in packaging that includes specific NDC numbers, which should be retained for future reference regarding full labeling. It is essential to store the product at a temperature range of 20° to 25°C (68° to 77°F) to ensure its stability and efficacy. Additionally, the carton should be kept for future reference to access complete labeling information.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Walgreens Moisturizing Ultra Fine Mist with Aloe, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)